Intellia Therapeutics Inc logo

Intellia Therapeutics Inc

2
NAS:NTLA (USA)  
$ 32.45 -0.21 (-0.64%) 03:46 PM EST
At Loss
P/B:
2.87
Volume:
1.24M
Avg Vol (2M):
1.70M
Also Trade In:
Volume:
1.24M
At Loss
Avg Vol (2M):
1.70M

Business Description

Description
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Name Current Vs Industry Vs History
Cash-To-Debt 7.91
Equity-to-Asset 0.81
Debt-to-Equity 0.11
Debt-to-EBITDA -0.23
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.35
Distress
Grey
Safe
Beneish M-Score 8.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 76.11
9-Day RSI 69.87
14-Day RSI 64.93
6-1 Month Momentum % -32.98
12-1 Month Momentum % -38.01

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.67
Quick Ratio 8.67
Cash Ratio 7.92
Days Sales Outstanding 114.06

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12
Shareholder Yield % -4.72

Financials (Next Earnings Date:2024-05-03 Est.)

NTLA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NTLA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Intellia Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 36.275
EPS (TTM) ($) -5.41
Beta 1.92
Volatility % 57.18
14-Day RSI 64.93
14-Day ATR ($) 2.0184
20-Day SMA ($) 28.1295
12-1 Month Momentum % -38.01
52-Week Range ($) 22.665 - 47.48
Shares Outstanding (Mil) 96.11

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Intellia Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Intellia Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Intellia Therapeutics Inc Frequently Asked Questions

What is Intellia Therapeutics Inc(NTLA)'s stock price today?
The current price of NTLA is $32.45. The 52 week high of NTLA is $47.48 and 52 week low is $22.67.
When is next earnings date of Intellia Therapeutics Inc(NTLA)?
The next earnings date of Intellia Therapeutics Inc(NTLA) is 2024-05-03 Est..
Does Intellia Therapeutics Inc(NTLA) pay dividends? If so, how much?
Intellia Therapeutics Inc(NTLA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1